Stock analysts at StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX – Get Free Report) in a research note issued on Saturday. The firm set a “sell” rating on the stock.
Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $2.50 price objective on shares of VolitionRx in a report on Thursday, May 16th.
Read Our Latest Stock Analysis on VNRX
VolitionRx Stock Down 4.1 %
VolitionRx (NYSE:VNRX – Get Free Report) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. The firm had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.27 million. On average, equities research analysts anticipate that VolitionRx will post -0.31 earnings per share for the current fiscal year.
Institutional Trading of VolitionRx
A hedge fund recently bought a new stake in VolitionRx stock. Silverberg Bernstein Capital Management LLC acquired a new stake in VolitionRx Limited (NYSE:VNRX – Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned 0.19% of VolitionRx as of its most recent SEC filing. Institutional investors own 8.09% of the company’s stock.
About VolitionRx
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Further Reading
- Five stocks we like better than VolitionRx
- What Investors Need to Know to Beat the Market
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Compound Interest and Why It Matters When Investing
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.